PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28962190-0	2017	Metformin in combination with rosiglitazone contribute to the increased serum adiponectin levels in people with type 2 diabetes mellitus.	Rosiglitazone	30-43	adiponectin, C1Q and collagen domain containing	Homo sapiens	78-89	
28962190-1	2017	To evaluate how metformin plus rosiglitazone affect serum adiponectin levels in people suffering from type 2 diabetes mellitus (T2DM), 240 patients having T2DM were selected in this cohort study.	Rosiglitazone	31-44	adiponectin, C1Q and collagen domain containing	Homo sapiens	58-69	
28962190-6	2017	Further subgroup analyses indicated that combination therapy of metformin and rosiglitazone may increase the amount of serum adiponectin in T2DM sufferers among the majority subgroups (all P<0.05).	Rosiglitazone	78-91	adiponectin, C1Q and collagen domain containing	Homo sapiens	125-136	
28962190-7	2017	The combination of metformin and rosiglitazone treatment increased serum adiponectin levels, suggesting that metformin plus rosiglitazone therapy is a suitable choice to treat T2DM.	Rosiglitazone	33-46	adiponectin, C1Q and collagen domain containing	Homo sapiens	73-84	
28962190-7	2017	The combination of metformin and rosiglitazone treatment increased serum adiponectin levels, suggesting that metformin plus rosiglitazone therapy is a suitable choice to treat T2DM.	Rosiglitazone	124-137	adiponectin, C1Q and collagen domain containing	Homo sapiens	73-84